Flagship explainer
What drives Tango Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$102M | FY2025 |
| |
| Income before tax | −$102M | FY2025 |
|
| Operating income | −$111M | FY2025 |
|
| $62.4M | FY2025 |
| |
| Ending assets | $399M | FY2025 |
|
| Beginning assets | $316M | FY2024 |
|
| $346M | FY2025 |
| |
| $200M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001193125-26-092518